论文部分内容阅读
目的观察阿昔洛韦治疗小儿水痘的临床疗效和安全性。方法将120例水痘患儿随机分为对照和治疗2组。对照组60例,用三氮唑核昔(利巴韦林)注射液10~15 mg/(kg.d),每日1次静脉滴注,疗程为5~7 d;治疗组60例,在对照组的基础上加用阿昔洛韦注射液10 mg/(kg.d),每日1次静脉滴注,疗程4~6 d。结果治疗组平均治愈时间(4.3±0.5)d,对照组平均治愈时间(5.8±0.6)d,2组差异有统计学意义,治疗组痊愈率为100%,对照组痊愈率为96.7%,2组疗效差异无统计学意义,2组治疗前后患儿血尿常规、肝肾功能检查未见异常。结论阿昔洛韦治疗小儿水痘疗效高,安全可靠,可供临床使用。
Objective To observe the clinical efficacy and safety of acyclovir in the treatment of chickenpox in children. Methods 120 cases of chicken pox were randomly divided into control group and treatment group. Control group of 60 cases, with ribavirin (Ribavirin) injection 10 ~ 15 mg / (kg.d), daily intravenous infusion, treatment for 5 to 7 d; the treatment group of 60 patients, On the basis of the control group, add acyclovir injection 10 mg / (kg.d) intravenously once daily for 4 ~ 6 days. Results The average healing time was 4.3 ± 0.5 days in the treatment group and 5.8 ± 0.6 days in the control group. The difference between the two groups was statistically significant. The cure rate was 100% in the treatment group and 96.7% in the control group. There was no significant difference in the curative effect between the two groups. The hematuria routine before and after treatment in both groups showed no abnormalities in liver and kidney function tests. Conclusion Aciclovir treatment of children with chickenpox with high efficacy, safety and reliability, for clinical use.